Literature DB >> 10685989

Severe retinopathy of prematurity and its association with different rates of survival in infants of less than 1251 g birth weight.

J Vyas1, D Field, E S Draper, G Woodruff, A R Fielder, J Thompson, N J Shaw, D Clark, R Gregson, J Burke, G Durbin.   

Abstract

BACKGROUND: There is controversy over whether improved survival of preterm infants has resulted in a higher incidence of severe (grade 3 or greater) retinopathy of prematurity (ROP). AIM: To compare survival rates and rates of > or = stage 3 ROP-that is, with a high risk of sequelae-in preterm infants in five English cities where, anecdotally, the incidence of ROP is reported to show considerable variation.
METHODS: All infants of birth weight < 1500 g and or gestational age < 32 weeks, born in 1994 in one of the cities or transferred in within 48 hours, were studied. The populations were adjusted for case mix variation using CRIB (clinical risk index for babies, a disease severity scoring system). The incidence of severe ROP, the actual death rate, and that adjusted for disease severity were determined.
RESULTS: The rate of severe ROP per 1000 births was higher in city 1 than in all the other cities. This increase in comparison with city 2 and city 4 was significant (city 1, 167 (95% confidence interval (CI) 96 to 260); city 2, 24 (6 to 59); city 4, 16 (1 to 84)). A significant difference was not seen between city 1 and cities 3 (23 (1 to 120)) and 5 (74 (21 to 79)). The relative risk of developing severe ROP in city 1 compared with all the other cities was 5.5 (2.5 to 11.9). The actual death rate per 1000 births in city 1 was significantly lower than that predicted by modelling death against CRIB score (city 1: actual 270; predicted 385 (95% CI 339 to 431)). In contrast, the other cities had actual death rates as predicted, or worse than predicted, by CRIB.
INTERPRETATION: A significantly higher incidence of severe ROP was identified in one of the five cities studied. Variation in survival rates among high risk infants may explain this observation.

Entities:  

Mesh:

Year:  2000        PMID: 10685989      PMCID: PMC1721052          DOI: 10.1136/fn.82.2.f145

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  20 in total

1.  Epidemiology of retinopathy of prematurity.

Authors:  Y K Ng; A R Fielder; D E Shaw; M I Levene
Journal:  Lancet       Date:  1988-11-26       Impact factor: 79.321

2.  Attitudes to viability of preterm infants and their effect on figures for perinatal mortality.

Authors:  A C Fenton; D J Field; E Mason; M Clarke
Journal:  BMJ       Date:  1990-02-17

3.  Retinopathy of prematurity in middle-income countries.

Authors:  C Gilbert; J Rahi; M Eckstein; J O'Sullivan; A Foster
Journal:  Lancet       Date:  1997-07-05       Impact factor: 79.321

4.  Increased survival of low birth weight infants: impact on the incidence of retinopathy of prematurity.

Authors:  P H Valentine; J C Jackson; R E Kalina; D E Woodrum
Journal:  Pediatrics       Date:  1989-09       Impact factor: 7.124

5.  Antenatal dexamethasone and decreased severity of retinopathy of prematurity.

Authors:  R D Higgins; A L Mendelsohn; M J DeFeo; R Ucsel; K D Hendricks-Munoz
Journal:  Arch Ophthalmol       Date:  1998-05

6.  Increased survival and deteriorating developmental outcome in 23 to 25 week old gestation infants, 1990-4 compared with 1984-9.

Authors:  H C Emsley; S P Wardle; D G Sims; M L Chiswick; S W D'Souza
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

7.  Cost of preventing retrolental fibroplasia?

Authors:  K W Cross
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

8.  Changing overall workload in neonatal units.

Authors:  D J Field; A D Milner; I E Hopkin; R J Madeley
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

9.  Retinopathy of prematurity: risk factors in a prospective population-based study.

Authors:  B A Darlow; L J Horwood; R S Clemett
Journal:  Paediatr Perinat Epidemiol       Date:  1992-01       Impact factor: 3.980

10.  Retinopathy of prematurity in extremely low birth weight infants.

Authors:  C G Keith; L W Doyle
Journal:  Pediatrics       Date:  1995-01       Impact factor: 7.124

View more
  8 in total

1.  Reduced incidence of retinopathy of prematurity.

Authors:  E Rowlands; A C Ionides; S Chinn; H Mackinnon; C C Davey
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

Review 2.  Retinopathy of prematurity: recent advances in our understanding.

Authors:  C M Wheatley; J L Dickinson; D A Mackey; J E Craig; M M Sale
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

Review 3.  Retinopathy of prematurity: recent advances in our understanding.

Authors:  C M Wheatley; J L Dickinson; D A Mackey; J E Craig; M M Sale
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-09       Impact factor: 5.747

Review 4.  Neonatal disease severity scoring systems.

Authors:  J S Dorling; D J Field; B Manktelow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-01       Impact factor: 5.747

5.  Variation in rates of severe retinopathy of prematurity among neonatal intensive care units in the Australian and New Zealand Neonatal Network.

Authors:  B A Darlow; J L Hutchinson; J M Simpson; D J Henderson-Smart; D A Donoghue; N J Evans
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

6.  Incidence of ROP in two consecutive Swedish population based studies.

Authors:  E Larsson; B Carle-Petrelius; G Cernerud; L Ots; A Wallin; G Holmström
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

7.  Maintaining optimal oxygen saturation in premature infants.

Authors:  Yoke Yen Lau; Yih Yann Tay; Varsha Atul Shah; Pisun Chang; Khuan Tai Loh
Journal:  Perm J       Date:  2011

8.  Retinopathy of prematurity in port harcourt, Nigeria.

Authors:  Adedayo O Adio; Rosemary O Ugwu; Chidi G Nwokocha; Augusta U Eneh
Journal:  ISRN Ophthalmol       Date:  2014-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.